---

---

tags : Trial    symbols : PLRX   

save search

---

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -27.59% | O: -3.62% H: 0.0% C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics

---

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| -54.35% | O: -1.24% H: 0.0% C: 0.0%
PLRX | $12.85 1.98% 16K |

Health Technology

| -13.58% | O: 7.89% H: 11.25% C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics

---

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Published: 2023-09-25 (Crawled : 20:00) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -13.58% | O: 7.89% H: 11.25% C: 5.98%
trial therapeutics

---

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
Published: 2023-08-09 (Crawled : 12:20) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -30.65% | O: -0.66% H: 0.83% C: 0.72%
fibrosis bexotegrast trial therapeutics

---

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
Published: 2023-04-30 (Crawled : 20:20) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -55.4% | O: -15.04% H: 0.0% C: -7.04%
positive bexotegrast trial therapeutics

---

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Published: 2023-03-13 (Crawled : 12:20) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -54.97% | O: -1.64% H: 5.52% C: 2.47%
pln-7480 trial therapeutics review positive sclerosing cholangitis

---

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| -44.02% | O: 55.66% H: 4.17% C: -13.58%
fibrosis trial therapeutics positive phase 2b

---

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX | $12.85 1.98% 16K |

Health Technology

| -34.65% | O: 1.76% H: 4.84% C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b

---

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Published: 2022-07-10 (Crawled : 00:00) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| 41.89% | O: 80.29% H: 43.66% C: 43.66%
pln-7480 fibrosis trial therapeutics positive phase 2b

---

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
Published: 2022-06-24 (Crawled : 12:20) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| 51.81% | O: 0.96% H: 12.77% C: -2.39%
preclinical trial therapeutics pre-clinical phase 2b

---

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
PLRX | $12.85 1.98% 16K |

Health Technology

| 30.57% | O: -0.41% H: 0.0% C: 0.0%
pln-7480 health phase 1b trial therapeutics phase 1 positive phase 2b

---

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 23:00) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| 49.64% | O: 0.71% H: 13.92% C: 13.8%
pln-7480 phase 2 fibrosis trial therapeutics positive enroll phase 2b

---

Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
PLRX | $12.85 1.98% 16K |

Health Technology

| -33.79% | O: 15.61% H: 9.86% C: -12.91%
phase 2 fibrosis positive results trial imaging phase 2b

---

Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Published: 2021-09-03 (Crawled : 21:00) - globenewswire.com
PLRX | $12.85 1.98% 16K |

Health Technology

| Email alert Add to watchlist
phase 2 ongoing fibrosis trial pln-7480 phase 2b

---

Gainers vs Losers

89%

11%

Top 10 Gainers

MTTR | News M | $4.65 167.24% 9.8M |

AGBA | $2.46 96.8% 28M |

Finance

EDBL | News | $6.94 84.57% 1.4M |

CZOO | $7.74 55.11% 2.7M |

ZAPP | $6.02 35.59% 95K |

n/a

OPRT | News | $3.01 33.78% 6.8M |

Finance

MLEC | $1.81 29.29% 2M |

n/a

MTC | $2.0 28.21% 1.7M |

Technology Services

PEGY | $0.0586 27.95% 130M |

Manufacturing

VNRX | $0.759 26.5% 390K |

Health Technology

---

Your saved searches

---